Tirzepatide
LY3298176, dual GIP/GLP-1 receptor agonist, twincretin, Mounjaro, Zepbound
Tirzepatide is a single 39-amino-acid peptide that activates two different incretin receptors at once, GIP and GLP-1. In head-to-head trials it produced greater weight loss and greater glucose lowering than semaglutide. Like semaglutide, it has a genuine large-scale randomised evidence base, which makes it an outlier among peptides sold online.
Mechanism
Tirzepatide is built on the backbone of glucose-dependent insulinotropic polypeptide (GIP) rather than GLP-1, but it has been engineered to bind and activate both the GIP receptor and the GLP-1 receptor. It is a balanced agonist at the GIP receptor and a comparatively biased, lower-potency agonist at the GLP-1 receptor, where it favours cAMP generation over beta-arrestin recruitment. That bias reduces receptor internalisation and desensitisation, and is one proposed reason why it achieves greater efficacy without proportionally worse gastrointestinal tolerability. This remains a mechanistic hypothesis rather than a demonstrated explanation of the clinical difference.
The GLP-1 arm delivers the familiar effects: glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying and central appetite suppression via the hypothalamus and hindbrain. The GIP arm is more contested. GIP receptor activation appears to add insulinotropic effect in the beta cell, to act on adipose tissue to improve lipid buffering and insulin sensitivity, and to act centrally in the hypothalamus to further reduce food intake. Confusingly, GIP receptor antagonism also produces weight loss in animal models, and the field has not resolved why agonism and antagonism can point the same direction; one explanation is that sustained agonism causes functional receptor desensitisation. Two alpha-aminoisobutyric acid substitutions confer resistance to dipeptidyl peptidase-4, and a C20 diacid chain attached through a gamma-glutamyl and bis-AEEA linker to lysine 20 drives albumin binding and the roughly five-day half-life.
What the research shows
SURPASS-2 provided the head-to-head comparison that established tirzepatide's position: in 1,879 people with type 2 diabetes on metformin, all three tirzepatide doses produced greater HbA1c reduction and greater weight loss than semaglutide 1 mg weekly, with weight change of -7.6 to -11.2 kg versus -5.7 kg. SURMOUNT-1 then tested it in 2,539 adults with obesity and without diabetes over 72 weeks, producing mean weight reductions of -15.0%, -19.5% and -20.9% at 5, 10 and 15 mg against -3.1% on placebo, the largest effect any pharmacological agent had shown in a phase 3 obesity trial at the time.
The evidence has since extended beyond weight and glucose. SURMOUNT-OSA randomised 469 adults across two trials with moderate to severe obstructive sleep apnoea and obesity and found large reductions in the apnoea-hypopnoea index, leading to FDA approval for that indication in December 2024, the first drug ever licensed for obstructive sleep apnoea. SUMMIT randomised 731 people with heart failure with preserved ejection fraction and obesity and reported a reduction in the composite of cardiovascular death or worsening heart failure. SURPASS-CVOT, the dedicated cardiovascular outcome trial in type 2 diabetes, has now reported; this audit could not confirm its identifiers, so it is listed below as unverified. Crucially, SURPASS-CVOT was an active-comparator trial against dulaglutide rather than a placebo-controlled trial, so it establishes that tirzepatide is not cardiovascularly inferior to an agent of proven benefit rather than quantifying benefit against placebo. That is a genuinely different question from the one SELECT answered for semaglutide, and the distinction is routinely blurred in secondary coverage.
Evidence assessment
High-quality evidence
Multiple large randomised placebo-controlled phase 3 trials with head-to-head active comparators, plus outcome trials in sleep apnoea and heart failure, with all four peer-reviewed citations independently verified against PubMed and ClinicalTrials.gov, and approved regulatory labelling in the US, UK and EU.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes High-quality evidence
All tirzepatide doses were superior to semaglutide 1 mg weekly for HbA1c reduction and body weight change, with weight loss of 7.6 to 11.2 kg versus 5.7 kg.
Tirzepatide Once Weekly for the Treatment of Obesity High-quality evidence
Mean weight change was -15.0%, -19.5% and -20.9% at 5, 10 and 15 mg respectively versus -3.1% with placebo.
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity High-quality evidence
Tirzepatide substantially reduced the apnoea-hypopnoea index compared with placebo in adults with moderate to severe obstructive sleep apnoea and obesity, both with and without concurrent positive airway pressure therapy.
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity High-quality evidence
Tirzepatide reduced the composite risk of cardiovascular death or worsening heart failure and improved health status in patients with HFpEF and obesity.
SURMOUNT-5: tirzepatide versus semaglutide in adults with obesity (head-to-head randomised trial) High-quality evidence
Tirzepatide produced greater mean body weight reduction than semaglutide 2.4 mg weekly in adults with obesity and without diabetes.
SURPASS-CVOT: cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes Mixed evidence
Tirzepatide met the prespecified non-inferiority criterion against dulaglutide for major adverse cardiovascular events; because the comparator was an active agent rather than placebo, the trial does not quantify cardiovascular benefit relative to no treatment.
Safety
The adverse event profile closely resembles that of GLP-1 receptor agonists and is dominated by dose-related gastrointestinal effects: nausea, vomiting, diarrhoea, constipation, dyspepsia and abdominal pain, worst during dose escalation. Discontinuation for adverse events in SURMOUNT-1 was roughly 4 to 7% depending on dose, against about 3% on placebo. Labelled warnings include acute pancreatitis, gallbladder disease, acute kidney injury from volume depletion, hypersensitivity reactions, and diabetic retinopathy complications in those with pre-existing retinopathy. As with semaglutide, rodent studies showed thyroid C-cell tumours, producing a contraindication in personal or family history of medullary thyroid carcinoma or MEN2, with the human relevance unestablished. Hypoglycaemia risk is low as monotherapy but rises materially when combined with insulin or sulfonylureas. Delayed gastric emptying raises aspiration concerns around general anaesthesia and endoscopy. A substantial share of the weight lost is lean mass, and the consequences of that over years rather than months are not yet characterised. Because tirzepatide is heavily counterfeited and sold through unregulated channels, product identity and concentration are a real and separate hazard from the pharmacology.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | Licensed by the MHRA for type 2 diabetes and for weight management alongside a reduced-calorie diet and increased physical activity. Prescription-only. NICE has issued technology appraisal guidance covering NHS use in weight management, with a phased implementation approach reflecting capacity constraints. |
| United States | FDA approved for type 2 diabetes (2022), chronic weight management in obesity or overweight with a weight-related comorbidity (2023), and moderate to severe obstructive sleep apnoea in adults with obesity (December 2024). Prescription-only. |
| WADA (sport) | Not prohibited. Dual GIP/GLP-1 receptor agonists are not named on the WADA Prohibited List in or out of competition. |
Questions
The honest answer is that it is not fully settled. GIP receptor activation appears to add central appetite suppression via hypothalamic pathways and to improve how adipose tissue handles lipid, on top of the GLP-1 effects. The complication is that GIP receptor antagonists also cause weight loss in animal models, which suggests sustained agonism may work partly by desensitising the receptor. Both mechanisms are actively debated in the literature.
The picture is more complete than it was, but it is not equivalent to semaglutide's. SUMMIT showed benefit in a specific population, heart failure with preserved ejection fraction plus obesity. SURPASS-CVOT, the dedicated cardiovascular outcome trial, has reported and met non-inferiority, but its comparator was dulaglutide rather than placebo. That design answers whether tirzepatide is cardiovascularly at least as good as an established agent; it does not measure benefit against no treatment the way SELECT did for semaglutide. Anyone quoting SURPASS-CVOT as proof that tirzepatide 'prevents heart attacks' is overreading an active-comparator result.
Body composition substudies of both tirzepatide and semaglutide indicate roughly a quarter of the total mass lost is lean tissue, which is broadly in line with what happens during equivalent weight loss from caloric restriction. Whether that matters functionally over years, particularly in older people, is an open question and a legitimate reason for caution. There is no good evidence that any of the muscle-preservation peptides marketed alongside these drugs solve the problem.
This library does not cover pricing or access routes. NICE technology appraisal guidance sets out the criteria under which tirzepatide is funded for weight management on the NHS, and implementation has been phased. Anyone with a clinical question about eligibility should raise it with a GP or a specialist weight management service rather than rely on an educational reference.